2022: Predictions for medical and healthcare industry
2022 is going to be the year of opportunities and innovations from the medical industry in India
2022 is going to be the year of opportunities and innovations from the medical industry in India
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
It is used for the treatment of advanced colorectal and gastric cancer
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Second interchangeable biosimilar product approved by agency
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Subscribe To Our Newsletter & Stay Updated